Intravenous Immunoglobulin Therapy for Refractory Myositis

Masato MORIGUCHI; Takahiro SUZUKI; Mutsuto TATEISHI; Masako HARA; Sadao KASHIWAZAKI

doi:10.2169/internalmedicine.35.663

Masato MORIGUCHI, Takahiro SUZUKI, Mutsuto TATEISHI, Masako HARA, Sadao KASHIWAZAKI

Author information

Keywords: polymyositis, dermatomyositis, interstitial pneumonia, intravenous cyclophosphamide therapy

JOURNAL FREE ACCESS

1996 Volume 35 Issue 8 Pages 663-667

DOI https://doi.org/10.2169/internalmedicine.35.663

Details

Abstract

The efficacy of polyvalent intravenous immunoglobulin therapy (IVIG) was evaluated in three patients with refractory myositis. Patients refractory to conventional therapy, such as corticosteroid administration, corticosteroid or cyclophosphamide pulse therapy [2 with dermatomyositis (DM), 1 with polymyositis (PM)] were treated with IVIG (0.4 g/kg daily) for 5 days. Clinical improvement was apparent within 1-2 months after IVIG and persisted for 19-23 months (DM patients) and 12 months (PM patient). No adverse effects were observed. Thus, IVIG may be considered an effective therapy for refractory myositis.
(Internal Medicine 35: 663-667, 1996)

Corresponding author

Register with J-STAGE for free!